Ticker Hub
TGTX — AI Analysis & Sentiment
5 recent AI-generated analyses for TGTX. Sentiment and confidence insights updated continuously.
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
The publication of strong post-hoc data for BRIUMVI reinforces its efficacy in treatment-naïve MS patients. This strengthens the commercial outlook...
Jun 1, 2026TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
The positive Phase 3 results for BRIUMVI's simplified dosing regimen are a strong catalyst. This should enhance market adoption and future sales fo...
May 27, 2026TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics' presentation of new clinical data for BRIUMVI shows improved patient outcomes and disease control, which is expected to strengthen...
May 26, 2026TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported better-than-expected first-quarter results and significantly increased its full-year revenue outlook for BRIUMVI, its key ...
May 6, 2026Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
TG Therapeutics' achievement of a clinical milestone for Azer-Cel signals crucial pipeline progress, yet the market has shown a negative reaction. ...
Mar 12, 2026